Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-19-060476
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-13 17:35:50
Reporting Period:
2019-12-12
Accepted Time:
2019-12-13 17:35:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1702283 J. Michael Yang C/o Acadia Pharmaceuticals Inc.
3611 Valley Centre Drive, Ste. 300
San Diego CA 92130
Evp And Cco No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-12-12 22,500 $19.98 24,999 No 4 M Direct
Common Stock Acquisiton 2019-12-12 10,000 $21.28 34,999 No 4 M Direct
Common Stock Acquisiton 2019-12-12 72,979 $35.86 107,978 No 4 M Direct
Common Stock Disposition 2019-12-12 100,447 $44.49 7,531 No 4 S Direct
Common Stock Disposition 2019-12-12 5,032 $43.74 2,499 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2019-12-12 22,500 $0.00 22,500 $19.98
Common Stock Stock Option (Right to Buy) Disposition 2019-12-12 10,000 $0.00 10,000 $21.28
Common Stock Stock Option (Right to Buy) Disposition 2019-12-12 72,979 $0.00 72,979 $35.86
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
577,500 2028-04-17 No 4 M Direct
30,000 2028-10-14 No 4 M Direct
312,500 2027-03-28 No 4 M Direct
Footnotes
  1. Includes 876 shares of the Issuer's common stock acquired by the reporting person on November 15, 2017 pursuant to an employee stock purchase program.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2019.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.755 to $44.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.67 to $43.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  5. 25% of the 600,000 shares originally subject to the Stock Option vested and became exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments
  6. 25% of the 40,000 shares originally subject to the Stock Option vested and became exercisable on October 15, 2019. The remaining shares vest and become excercisable thereafter in 36 equal monthly installments.
  7. 25% of the 400,000 shares originally subject to the stock option vested and became exercisable on March 29, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.